Skip to main content
. 2021 Sep 25;24(10):103173. doi: 10.1016/j.isci.2021.103173

Figure 5.

Figure 5

ETS pathway is a key regulator for SLFN11 expression in GOF mutant leukemic cells

(A–C) ETS family proteins in MOLT4, CCRF-CEM, and HEL cells treated with cerdulatinib (40 μM) for the indicated times.

(D and E) Expression of ETS-1 after release of cerdulatinib treatment (40 μM, 24 h) in MOLT4 and HEL cells.

(F) Protein expressions of ETS-1 and FLI-1 detected by Western blotting in MOLT4 and CCRF-CEM cells treated with MK-2206 (20 μM, AKT inhibitor) and/or SCH772984 (20 μM, ERK inhibitor) for 24 h.

(G) Quantitation of SLFN11 protein expression in 3 independent experiments as shown in panel (F). The error bars represent SD; ∗p = 0.01 (MOLT4), ∗p = 0.023 (CCRF-CEM), ∗∗p = 0.002, ∗∗∗p < 0.001 with ordinary one-way ANOVA test and Tukey’s multiple comparisons test.

(H) Protein expression of SLFN11 and ETS proteins in MOLT4 cells treated with TK216 (30 μM, ETS inhibitor) as the indicated time points.

(I) Quantitation of SLFN11 and ETS-1 protein expression as shown in panel (H). Error bars represent SD (N = 2); ∗∗p = 0.006 (SLFN11; 0 vs. 4 h), ∗∗p = 0.004 (SLFN11; 0 vs. 6 h), †p = 0.018 with ordinary one-way ANOVA test and Tukey’s multiple comparisons test.

(J) Quantitation of SLFN11 and ETS protein expression in MOLT4 treated with the indicated concentrations of TK216 for 24 h as shown in Figure S5I. Error bars represent SD; ∗∗p = 0.006 (SLFN11), ∗∗∗p < 0.001 (SLFN11), ††p = 0.004 (ETS-1), †††p < 0.001 (ETS-1) with ordinary one-way ANOVA test and Tukey’s multiple comparisons test.